Literature DB >> 22949529

G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.

Alexander G Vandell1, Maximilian T Lobmeyer, Brian E Gawronski, Taimour Y Langaee, Yan Gong, John G Gums, Amber L Beitelshees, Stephen T Turner, Arlene B Chapman, Rhonda M Cooper-DeHoff, Kent R Bailey, Eric Boerwinkle, Carl J Pepine, Stephen B Liggett, Julie A Johnson.   

Abstract

G protein-coupled receptor kinases (GRKs) are important regulatory proteins for many G protein-coupled receptors, but little is known about GRK4 pharmacogenetics. We hypothesized that 3 nonsynonymous GRK4 single-nucleotide polymorphisms, R65L (rs2960306), A142V (rs1024323), and A486V (rs1801058), would be associated with blood pressure response to atenolol, but not hydrochlorothiazide, and would be associated with long-term cardiovascular outcomes (all-cause death, nonfatal myocardial infarction, nonfatal stroke) in participants treated with an atenolol-based versus verapamil-SR-based antihypertensive strategy. GRK4 single-nucleotide polymorphisms were genotyped in 768 hypertensive participants from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) trial. In whites and blacks, increasing copies of the variant 65L-142V haplotype were associated with significantly reduced atenolol-induced diastolic blood pressure lowering (-9.1±6.8 versus -6.8±7.1 versus -5.3±6.4 mm Hg in participants with 0, 1, and 2 copies of 65L-142V, respectively; P=0.0088). One thousand four hundred sixty participants with hypertension and coronary artery disease from the INternational VErapamil SR/Trandolapril STudy (INVEST) were genotyped, and variant alleles of all 3 GRK4 single-nucleotide polymorphisms were associated with increased risk for adverse cardiovascular outcomes in an additive fashion, with 486V homozygotes reaching statistical significance (odds ratio, 2.29 [1.48-3.55]; P=0.0002). These effects on adverse cardiovascular outcomes were independent of antihypertensive treatment. These results suggest that the presence of GRK4 variant alleles may be important determinants of blood pressure response to atenolol and risk for adverse cardiovascular events. The associations with GRK4 variant alleles were stronger in patients who were also ADRB1 389R homozygotes, suggesting a potential interaction between these 2 genes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22949529      PMCID: PMC3462355          DOI: 10.1161/HYPERTENSIONAHA.112.198721

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  33 in total

1.  Association study with 33 single-nucleotide polymorphisms in 11 candidate genes for hypertension in Chinese.

Authors:  Dongfeng Gu; Shaoyong Su; Dongliang Ge; Shufeng Chen; Jianfeng Huang; Biao Li; Runsheng Chen; Boqin Qiang
Journal:  Hypertension       Date:  2006-04-24       Impact factor: 10.190

2.  Blood pressure and renal sodium handling in relation to genetic variation in the DRD1 promoter and GRK4.

Authors:  Jan A Staessen; Tatiana Kuznetsova; Haifeng Zhang; Marc Maillard; Murielle Bochud; Sandra Hasenkamp; Judith Westerkamp; Tom Richart; Lutgarde Thijs; Xinli Li; Stefan-Martin Brand-Herrmann; Michel Burnier; Eva Brand
Journal:  Hypertension       Date:  2008-04-14       Impact factor: 10.190

3.  beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension.

Authors:  Jie Liu; Zhao-Qian Liu; Bang-Ning Yu; Fang-Hua Xu; Wei Mo; Gan Zhou; Ying-Zi Liu; Qing Li; Hong-Hao Zhou
Journal:  Clin Pharmacol Ther       Date:  2006-06-08       Impact factor: 6.875

4.  Association study of G protein-coupled receptor kinase 4 gene variants with essential hypertension in northern Han Chinese.

Authors:  Yaping Wang; Biao Li; Weiyan Zhao; Pei Liu; Qi Zhao; Shufeng Chen; Hongfan Li; Dongfeng Gu
Journal:  Ann Hum Genet       Date:  2006-11       Impact factor: 1.670

5.  Mechanisms of disease: the role of GRK4 in the etiology of essential hypertension and salt sensitivity.

Authors:  Robin A Felder; Pedro A Jose
Journal:  Nat Clin Pract Nephrol       Date:  2006-11

6.  A polymorphism of G-protein coupled receptor kinase5 alters agonist-promoted desensitization of beta2-adrenergic receptors.

Authors:  Wayne C H Wang; Kathryn A Mihlbachler; Eugene R Bleecker; Scott T Weiss; Stephen B Liggett
Journal:  Pharmacogenet Genomics       Date:  2008-08       Impact factor: 2.089

7.  A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure.

Authors:  Stephen B Liggett; Sharon Cresci; Reagan J Kelly; Faisal M Syed; Scot J Matkovich; Harvey S Hahn; Abhinav Diwan; Jeffrey S Martini; Li Sparks; Rohan R Parekh; John A Spertus; Walter J Koch; Sharon L R Kardia; Gerald W Dorn
Journal:  Nat Med       Date:  2008-04-20       Impact factor: 53.440

8.  beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.

Authors:  M A Pacanowski; Y Gong; R M Cooper-Dehoff; N J Schork; M D Shriver; T Y Langaee; C J Pepine; J A Johnson
Journal:  Clin Pharmacol Ther       Date:  2008-07-09       Impact factor: 6.875

9.  KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).

Authors:  Amber L Beitelshees; Yan Gong; Danxin Wang; Nicholas J Schork; Rhonda M Cooper-Dehoff; Taimour Y Langaee; Mark D Shriver; Wolfgang Sadee; Harm J Knot; Carl J Pepine; Julie A Johnson
Journal:  Pharmacogenet Genomics       Date:  2007-09       Impact factor: 2.089

10.  G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions.

Authors:  Vibha Bhatnagar; Daniel T O'Connor; Victoria H Brophy; Nicholas J Schork; Erin Richard; Rany M Salem; Caroline M Nievergelt; George L Bakris; John P Middleton; Keith C Norris; Jackson Wright; Leena Hiremath; Gabriel Contreras; Lawrence J Appel; Michael S Lipkowitz
Journal:  Am J Hypertens       Date:  2009-01-01       Impact factor: 2.689

View more
  30 in total

1.  Increased renal oxidative stress in salt-sensitive human GRK4γ486V transgenic mice.

Authors:  Zhenyu Diao; Laureano D Asico; Van Anthony M Villar; Xiaoxu Zheng; Santiago Cuevas; Ines Armando; Pedro A Jose; Xiaoyan Wang
Journal:  Free Radic Biol Med       Date:  2017-02-09       Impact factor: 7.376

2.  α1 -Adrenoceptor activation of PKC-ε causes heterologous desensitization of thromboxane receptors in the aorta of spontaneously hypertensive rats.

Authors:  Yingzi Zhao; Paul M Vanhoutte; Susan W S Leung
Journal:  Br J Pharmacol       Date:  2015-05-15       Impact factor: 8.739

Review 3.  Primary Pediatric Hypertension: Current Understanding and Emerging Concepts.

Authors:  Andrew C Tiu; Michael D Bishop; Laureano D Asico; Pedro A Jose; Van Anthony M Villar
Journal:  Curr Hypertens Rep       Date:  2017-09       Impact factor: 5.369

4.  Structure and Function of the Hypertension Variant A486V of G Protein-coupled Receptor Kinase 4.

Authors:  Samantha J Allen; Gopal Parthasarathy; Paul L Darke; Ronald E Diehl; Rachael E Ford; Dawn L Hall; Scott A Johnson; John C Reid; Keith W Rickert; Jennifer M Shipman; Stephen M Soisson; Paul Zuck; Sanjeev K Munshi; Kevin J Lumb
Journal:  J Biol Chem       Date:  2015-07-01       Impact factor: 5.157

Review 5.  The evolving impact of g protein-coupled receptor kinases in cardiac health and disease.

Authors:  Priscila Y Sato; J Kurt Chuprun; Mathew Schwartz; Walter J Koch
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

Review 6.  Progress and future aspects in genetics of human hypertension.

Authors:  Qi Zhao; Tanika N Kelly; Changwei Li; Jiang He
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

Review 7.  The renal dopaminergic system: novel diagnostic and therapeutic approaches in hypertension and kidney disease.

Authors:  Ines Armando; Prasad Konkalmatt; Robin A Felder; Pedro A Jose
Journal:  Transl Res       Date:  2014-07-25       Impact factor: 7.012

8.  Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy.

Authors:  Kimberly S Collins; Victoria M Pratt; Wesley M Stansberry; Elizabeth B Medeiros; Karthik Kannegolla; Marelize Swart; Todd C Skaar; Arlene B Chapman; Brian S Decker; Ranjani N Moorthi; Michael T Eadon
Journal:  Pharmacogenet Genomics       Date:  2019-01       Impact factor: 2.089

Review 9.  Hypertension pharmacogenomics: in search of personalized treatment approaches.

Authors:  Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

Review 10.  Pharmacogenetics and cardiovascular disease--implications for personalized medicine.

Authors:  Julie A Johnson; Larisa H Cavallari
Journal:  Pharmacol Rev       Date:  2013-05-17       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.